MedTrace Logo

Randomized Controlled Trial in Liver Transplant Recipients Treated in Steroid Sparing Regimen

NCT00286871 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2014-09-22

No results posted yet for this study

Summary

Liver transplant subjects will be given Mycophenolate (MMF) and Tacrolimus in order to help prevent post-transplant rejection.

Conditions

  • Chronic Hepatitis C
  • Organ Transplantation
  • Immunosuppression

Interventions

DRUG

Neoral

DRUG

Tacrolimus

Sponsors & Collaborators

Principal Investigators

  • Devai Desai, MD, PhD · Duke University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-02-28
Completion
2009-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00286871 on ClinicalTrials.gov